Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Wegovy maker Novo Nordisk and Zepbound manufacturer Eli Lilly directly ... authorization process under the new weight-loss drug benefit. Cigna has made numerous forays into the GLP-1 space.

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

Evernorth, the health services division of The Cigna Group, announced the benefit that will make popular weight loss medications Wegovy and Zepbound more available to patients. Through direct ...

Cigna's Evernorth is rolling out a new pharmacy ... Scripts arm it negotiated directly with the manufacturers for Wegovy and Zepbound—Novo Nordisk and Eli Lilly, respectively—to cap patients ...

Evernorth, the pharmacy benefits unit for health insurer ... patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a list price ...

Only half of health insurer Cigna's clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company's pharmacy benefits unit Evernorth ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...